36650-39-2Relevant articles and documents
Copper(II)-Catalyzed Reactions of α-Keto Thioesters with Azides via C-C and C-S Bond Cleavages: Synthesis of N-Acylureas and Amides
Maity, Rajib,Naskar, Sandip,Das, Indrajit
, p. 2114 - 2124 (2018/02/23)
Cu(II)-catalyzed reaction of α-keto thioesters with trimethylsilyl azide (TMSN3) proceeds with the transformation of the thioester group into urea through C-C and C-S bond cleavages, constituting a practical and straightforward synthesis of N-acylureas. When diphenyl phosphoryl azide (DPPA) is used instead as the azide source in an aqueous environment, primary amides are formed via substitution of the thioester group. The reactions are proposed to proceed through Curtius rearrangement of the initially formed α-keto acyl azide to generate an acyl isocyanate intermediate, which reacts further with an additional amount of azide or water and rearranges to afford the corresponding products. To demonstrate the potentiality of the method, one-step syntheses of pivaloylurea and isovaleroylurea, displaying anticonvulsant activities, have been carried out.
Regio- and diastereoselective synthesis of trans-dihydrofuran-3carboxamides by radical addition of 1,3-dicarbonyl compounds to acrylamides using manganese(III) acetate and determination of exact configuration by X-ray crystallography
Yilmaz, Mehmet,Ustalar, Ash,U?an, Bedriye,Pekel, A. Tar?k
, p. 79 - 91 (2018/05/09)
In this study, we investigated the radical addition of 1,3-dicarbonyl compounds to acrylamide derivatives including phenyl, 2-thienyl and 5-methyl-2-furyl groups mediated by manganese(III) acetate. trans-3-Carboxamide-dihydrofurans were obtained in modarate to good yields, as well as regio- and diastereoselectievly. Structural analyses of these compounds were made by NMR techniques such as HMBC and NOSY spectra. Also, exact configuration and structures of these (7b, 7i and 7j) compounds were determined by X-ray crystallography.
ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS
-
Paragraph 0037; 0038, (2013/04/10)
The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention also relates to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; especially use for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.
